In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently F…

Hematologic DisorderBleeding DisorderConnective Tissue Disorder+10 more

~Estimated

~$10 – $1,125

American Thrombosis and Hemostasis NetworkNCT04398628

Phase 4

Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A

This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) …

Factor VIII Deficiency, Congenital

~Estimated

~$10 – $8,750

Indiana Hemophilia &Thrombosis Center, Inc.NCT04567511

Phase 4

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in jo…

Factor VIII Deficiency

~Estimated

~$10 – $7,500

SanofiNCT06941870